Alexion Pharmaceuticals, Inc. has completed its acquisition of Synageva BioPharma Corp. through a merger of Synageva with and into a direct, wholly owned subsidiary of Alexion.

“The combination of our two companies provides us the exciting opportunity to build upon our collective strengths and talents to firmly establish Alexion as the global leader in serving patients with devastating and rare diseases,” said David Hallal, Chief Executive Officer at Alexion. “With Soliris, and the anticipated approvals of Strensiq and Kanuma, Alexion is poised to have three innovative products serving patients with four severe diseases in 2015 while also advancing the deepest and broadest pipeline in our history.”